Economy · World
Novartis Shares Fall After Multiple Drug Trial Setbacks
Novartis shares experienced a significant decline following multiple drug trial setbacks. The company's stock hit a 52-week low after the discontinuation of Minipress XL. Additionally, a drug intended for a muscular disease failed its trial, contributing to the stock's drop. One report indicated a 10% fall in the pharma major's stock after three such setbacks.
How outlets across the spectrum covered it
L 0 C 7 R 0
- Centre (7): Business Today, CNBC, Financial Times, Reuters, The Globe and Mail, The Hindu BusinessLine, The Wall Street Journal